Literature DB >> 20966552

Automated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI.

Stefan J Teipel1, Evangelia Kaza, Stefan Hadlich, Alexandra Bauer, Thomas Brüning, Anne-Sophie Plath, Markus Krohn, Katja Scheffler, Lary C Walker, Martin Lotze, Jens Pahnke.   

Abstract

In vivo imaging of amyloid-β (Aβ) load as a biomarker of Alzheimer's disease (AD) would be of considerable clinical relevance for the early diagnosis and monitoring of treatment effects. Here, we investigated automated quantification of in vivo T2 relaxation time as a surrogate measure of plaque load in the brains of ten AβPP/PS1 transgenic mice (age 20 weeks) using in vivo MRI acquisitions on a 7T Bruker ClinScan magnet. AβPP/PS1 mice present with rapid-onset cerebral β-amyloidosis, and were compared with eight age-matched, wild-type control mice (C57Bl/6J) that do not develop Aβ-deposition in brain. Data were analyzed with a novel automated voxel-based analysis that allowed mapping the entire brain for significant signal changes. In AβPP/PS1 mice, we found a significant decrease in T2 relaxation times in the deeper neocortical layers, caudate-putamen, thalamus, hippocampus, and cerebellum compared to wildtype controls. These changes were in line with the histological distribution of cerebral Aβ plaques and activated microglia. Grey matter density did not differ between wild-type mice and AβPP/PS1 mice, consistent with a lack of neuronal loss in histological investigations. High-field MRI with automated mapping of T2 time changes may be a useful tool for the detection of plaque load in living transgenic animals, which may become relevant for the evaluation of amyloid lowering intervention effects in future studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20966552      PMCID: PMC3030673          DOI: 10.3233/JAD-2010-101035

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  59 in total

1.  Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease.

Authors:  G Vanhoutte; I Dewachter; P Borghgraef; F Van Leuven; A Van der Linden
Journal:  Magn Reson Med       Date:  2005-03       Impact factor: 4.668

2.  Application of a non-linear image registration algorithm to quantitative analysis of T2 relaxation time in transgenic mouse models of AD pathology.

Authors:  M F Falangola; B A Ardekani; S-P Lee; J S Babb; A Bogart; V V Dyakin; R Nixon; K Duff; J A Helpern
Journal:  J Neurosci Methods       Date:  2004-12-07       Impact factor: 2.390

3.  Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly.

Authors:  J G Csernansky; L Wang; J Swank; J P Miller; M Gado; D McKeel; M I Miller; J C Morris
Journal:  Neuroimage       Date:  2005-04-15       Impact factor: 6.556

4.  In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice.

Authors:  Clifford R Jack; Thomas M Wengenack; Denise A Reyes; Michael Garwood; Geoffrey L Curran; Bret J Borowski; Joseph Lin; Gregory M Preboske; Silvina S Holasek; Gregor Adriany; Joseph F Poduslo
Journal:  J Neurosci       Date:  2005-10-26       Impact factor: 6.167

5.  A three-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy.

Authors:  Y Ma; P R Hof; S C Grant; S J Blackband; R Bennett; L Slatest; M D McGuigan; H Benveniste
Journal:  Neuroscience       Date:  2005-09-13       Impact factor: 3.590

6.  The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.

Authors:  Silke Vogelgesang; Rolf W Warzok; Ingolf Cascorbi; Christiane Kunert-Keil; Eike Schroeder; Heyo K Kroemer; Werner Siegmund; Lary C Walker; Jens Pahnke
Journal:  Curr Alzheimer Res       Date:  2004-05       Impact factor: 3.498

7.  In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent.

Authors:  Clifford R Jack; Michael Garwood; Thomas M Wengenack; Bret Borowski; Geoffrey L Curran; Joseph Lin; Gregor Adriany; Olli H J Gröhn; Roger Grimm; Joseph F Poduslo
Journal:  Magn Reson Med       Date:  2004-12       Impact factor: 4.668

8.  Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice.

Authors:  Maria F Falangola; Sang-Pil Lee; Ralph A Nixon; Karen Duff; Joseph A Helpern
Journal:  Neurochem Res       Date:  2005-02       Impact factor: 3.996

9.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report.

Authors:  Nigel J Cairns; Milos D Ikonomovic; Tammie Benzinger; Martha Storandt; Anne M Fagan; Aarti R Shah; Lisa Taylor Reinwald; Deborah Carter; Angela Felton; David M Holtzman; Mark A Mintun; William E Klunk; John C Morris
Journal:  Arch Neurol       Date:  2009-12

10.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

View more
  8 in total

1.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 2.  A review of β-amyloid neuroimaging in Alzheimer's disease.

Authors:  Paul A Adlard; Bob A Tran; David I Finkelstein; Patricia M Desmond; Leigh A Johnston; Ashley I Bush; Gary F Egan
Journal:  Front Neurosci       Date:  2014-10-31       Impact factor: 4.677

3.  In vivo microscopic voxel-based morphometry with a brain template to characterize strain-specific structures in the mouse brain.

Authors:  Keigo Hikishima; Yuji Komaki; Fumiko Seki; Yasuyuki Ohnishi; Hirotaka J Okano; Hideyuki Okano
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

Review 4.  Neuroimaging of Mouse Models of Alzheimer's Disease.

Authors:  Amandine Jullienne; Michelle V Trinh; Andre Obenaus
Journal:  Biomedicines       Date:  2022-01-28

5.  Correcting for imaging gradients-related bias of T2 relaxation times at high-resolution MRI.

Authors:  Natalie Bnaiahu; Noam Omer; Ella Wilczynski; Shir Levy; Tamar Blumenfeld-Katzir; Noam Ben-Eliezer
Journal:  Magn Reson Med       Date:  2022-06-06       Impact factor: 3.737

6.  Animal Models of Alzheimer's Disease: Utilization of Transgenic Alzheimer's Disease Models in Studies of Amyloid Beta Clearance.

Authors:  Tarja Malm; Johanna Magga; Jari Koistinaho
Journal:  Curr Transl Geriatr Exp Gerontol Rep       Date:  2012-01-19

7.  In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice.

Authors:  Ann-Marie Waldron; Cindy Wintmolders; Astrid Bottelbergs; Jonathan B Kelley; Mark E Schmidt; Sigrid Stroobants; Xavier Langlois; Steven Staelens
Journal:  Alzheimers Res Ther       Date:  2015-12-15       Impact factor: 6.982

8.  T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment.

Authors:  Alfie R Wearn; Volkan Nurdal; Esther Saunders-Jennings; Michael J Knight; Hanna K Isotalus; Serena Dillon; Demitra Tsivos; Risto A Kauppinen; Elizabeth J Coulthard
Journal:  Alzheimers Res Ther       Date:  2020-09-10       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.